advantages of ion mobility qtof for characterization of large … · 2016-09-11 · 30 31 32 33 34...
TRANSCRIPT
Add a New Dimension to your
Research Capability with
Agilent’s New Drift Ion Mobility
QTOF System
Ning Tang, Ph.D. Application Scientist
Anne Blackwell, Ph.D. Application Scientist
Advantages of Ion Mobility QTOF for
Characterization of Large Molecules
2014 Biopharma Roadshow 1
IM-QTOF Instrument Overview
2
System sensitivity optimized using electrodynamic ion funnels
to focus and transmit ions
Ion Mobility resolution optimized while maintaining QTOF
performance (mass resolution and accuracy)
Ion Fragmentation can be selected using standard QTOF
collision cell (CID)
Bandwidth of QTOF data acquisition and processing channel
was increased by 10 fold to match the ion mobility data rates
2014 Biopharma Roadshow
Ion Mobility System Design
3
Ionization source: Ion generation (ESI, AJS, Nano ESI, ChipCube, APCI etc.)
Front ion funnel: Efficient ion collection, desolvation and excess gas removal
Trap funnel: Ion accumulation and introducing ion packets into drift cell
Drift cell: Uniform low field ion mobility allows direct determination of accurate CCS (Ω)
Rear funnel: Efficient ion refocusing and introduction into mass analyzer
2014 Biopharma Roadshow
4
Detector Analyte
Ions
Gating
Optics
Ion Mobility Cell VH VL
Electric Field
Stacked ring ion guide gives linear field
Basic Operational Principle of Ion Mobility For Conventional DC Uniform Field IMS
𝑣 = 𝐾 𝐸 ∝𝑒 𝐸
𝑃 𝑇 Ω
2014 Biopharma Roadshow
5
Resolution Is Important!
Chromatographic Ion Mobility Mass
~seconds ~60 milli-seconds ~ 100 m seconds
2014 Biopharma Roadshow
6
530.7876
531.2889
531.7900
Ion Mobility Resolution
IMS
Resolution
𝑹 =𝒕𝒅
∆𝒕𝒅
=𝑳𝑬𝑸
𝟏𝟔𝒌𝑻𝒍𝒏𝟐
2014 Biopharma Roadshow
536.5960 536.9300
537.2644
7
Ion Mobility Resolution - Continued
Resolution = 84!
2014 Biopharma Roadshow
8
It’s All About Separation
Chromatography Ion Mobility Mass
2014 Biopharma Roadshow
~seconds ~60 milli-seconds ~ 100 m seconds
9
Chromatography Ion Mobility Mass
Peak Capacity = IMResolution x MassResolution x Orthogonality
Peak Capacity = 60 x 40,000 x 14% = 336,600 ~ 8-fold increase
Dwivedi P, Schultz AJ, Hill HH,
Metabolic profiling of human blood by high-resolution ion mobility mass spectrometry (IM-MS).
Int J Mass Spectrom 298:78–90. 2010
It’s All About Separation
2014 Biopharma Roadshow
10
Aldicarb-sulfone (C7H14N2O4S)
[M+Na]+ = 245.056649
Acetamiprid (C10H11ClN4)
[M+Na]+ = 245.056445
D mass is 0.2 mDa requires ~ 2,000,000 resolution !
Separation of Isobaric Pesticides
4 x10
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
19.441
17 17.5 18 18.5 19 19.5 20 20.5 21 21.5
6 x10
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
18.297
Drift Time (ms) 17 17.5 18 18.5 19 19.5 20 20.5 21 21.5
Aldicarb-sulfone
Acetamiprid
Drift Time (ms)
17 17.5 18 18.5 19 19.5 20 20.5 21 21.5
4x10
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5
+IMS DriftSpec (m/z: 245.013827-245.177238) (rt: 0.026-1.987 min) Aldicarbsulfone_A…
* 18.297
* 19.441
Counts vs. Acquisition Time (min)17 17.5 18 18.5 19 19.5 20 20.5 21 21.5
Theoretical Plot
IMS Drift
Separation
2014 Biopharma Roadshow
11
Resolving Structural Sugar Isomers C18H32O16
Melezitose
Raffinose
Resolving two isobaric tri-saccharides
2014 Biopharma Roadshow
12
Crude Bacterial Extract
0
20
40
50
500 1000 1500 2000
10
30
Mo
bilit
y D
rift
Tim
e (
ms)
Mass (Da)
Mass (Da)
1085 1086 1088 1089 1090 1087
Ion Mobility Drift Time (ms)
30 31 39 40 41 38 35 36 37 34 33 32
siamycin II
2014 Biopharma Roadshow
Working Hypothesis:
α-helical membrane spanning domains stay intact, and differ in drift-time from denatured peptides
400 600 800 1000 1200 1400 1600Drift Time (ms) vs. m/z
20
25
30
35
40
45
50
55
IMS-MS for Proteomics: Transmembrane Spanning Peptides
Characteristics:
• Large hydrophobic peptides
• X-ray: 7-helical domains
• Confirmation impacts function of membrane
• Membrane proteins are drug targets
1502.5 1503.0 1503.5 1504.0 1504.5 1505.0
Drift Time (ms) vs. m/z
34
36
38
40
42
44
1346 1347 1348 1349Drift Time (ms) vs. m/z
30
35
40
45
50
2014 Biopharma Roadshow
13
IMS-MS for Proteomics: Transmembrane Spanning Peptides
1429.5 1430.0 1430.5 1431.0 1431.5 1432.0
Drift Time (ms) vs. m/z
34
36
38
40
42
44
1502.5 1503.0 1503.5 1504.0 1504.5 1505.0
Drift Time (ms) vs. m/z
34
36
38
40
42
44
1694.5 1695.0 1695.5 1696.0
Drift Time (ms) vs. m/z
44
45
46
47
48
49
50
51
52
53
1346.5 1347.0 1347.5 1348.0
Drift Time (ms) vs. m/z
34
36
38
40
42
44
46
A B
C D
Figure Seq. Loc. Chg. State Helix A 1-40 [M+3H]3+ A B 1-82 [M+6H]6+ A-B C 83-159 [M+5H]5+ C-D-E
D 176-225 [M+4H]4+ F-G
2014 Biopharma Roadshow
14
15
LC – Ion Mobility – QTOF Protein Isoform Analysis
1346 1347 1348 1349 1350
Drift Time (ms) vs. m/z
28
30
32
34
36
38
2014 Biopharma Roadshow
Cry34AB
17
Resolving Isoforms of IgG2
Publication Paul Schnier, Synapt:
3uM direct infusion in 160 mM NH4Ac
1000 2000 3000 4000 5000 6000
Drift Time (ms) vs. m/z
0
20
40
60
80
100
4 x10
0
0.5
1
1.5
2
2.5
3
3.5
4
+IMS Drift Spectrum (0.00-106.65 ms) …
Counts vs. Drift Time (ms)
10 20 30 40 50 60 70 80 90 100
1000 2000 3000 4000 5000 6000
Drift Time (ms) vs. m/z
0
20
40
60
80
100
2014 Biopharma Roadshow
19
Lipid Analysis: Mixture of L-α-phosphotidylethanolamine (PE) Lipids
+2 lipids
+3 lipids
+4 lipids
+1 lipids
PE 19:N
PE 29:N PE 33:N
PE 34:N PE 36:N
PE 38:N
PE 46:N
PE 37:N
PE 40:N PE 44:N
PE 48:N
PE 59:N PE 61:N
PE 63:N
PE 90:N PE 92:N
PE 38:4 PE 38:6 PE 38:5 PE 38:3
PE 38:2 PE 38:1
PE 38:8 PE 38:7
PE 38:0
PE 37:1
Ion
Mo
bilit
y D
rift
Tim
e (
ms
)
2014 Biopharma Roadshow
0
20
40
50
500 1000 1500 2000
10
30
Mo
bilit
y D
rift
Tim
e (
ms)
Mass (Da)
Mass (Da)
1444 1446 1450 1452 1454 1448
Mass (Da)
1444 1446 1450 1452 1454 1448
Integrated Mass Spectrum:
Mobility-Filtered Mass Spectrum:
Why Ion Mobility? Specificity!
Crude bacterial extract, John McLean, Vanderbilt
2014 Biopharma Roadshow
20
21
2014 Biopharma Roadshow
Why Ion Mobility? Sensitivity!
y = 59060x - 350.63 R² = 0.9993
0
200000
400000
600000
0 2 4 6 8 10
Are
a R
esp
on
se
Sample Amount (pg)
Linear Dynamic Range
Sensitivity: ~ 50 fg of Reserpine
Dynamic range: ~ 3-4 orders
0E+00
1E+06
2E+06
3E+06
4E+06
5E+06
6E+06
single
puls
e
1 m
str
appin
g
single
puls
e
4m
str
appin
g
single
puls
e
8 m
str
ap t
ime
mult
i-puls
e
4x1
ms
trappin
g
mult
i-puls
e
8x1
ms
trappin
g
Sig
nal in
tensi
ty (
A.U
.)
• Integrated signal intensity for tetrakis decyl
ammonium bromide ion versus ion trapping time
for single pulse and multi-pulse experiments.
• These data indicate that for the same amount of
trapping time, multiplexing experiments result in at
least 10X higher signal intensity possibly due to
less space charge effects and detector saturation
issues.
Data browser can be used to “isolate” a group of glycans from matrix
Isolation of RNAseB native Glycans, Cathy Costello, Boston University
Why Ion Mobility? Selectivity!
2014 Biopharma Roadshow
22
Simplified view of RNaseB native
glycan
RNaseB native glycans
Glycan obscured by matrix is identified after cleaning up
background chemical noise using ion mobility
Why Ion Mobility? Selectivity!
2014 Biopharma Roadshow
23
𝐾0 =273 𝐾
𝑇
𝑃
760 Torr
𝐿2
𝑉𝑡𝑑
K0 = Reduced Ion Mobility
T = Temperature
P = Pressure
L = Drift length
V = Voltage Drop across drift region
td = Drift time
Determining Cross Sectional Areas
Ω = (18𝞹)1/2
16
𝑧𝑒
(𝑘𝑏𝑇)1/2 [1
𝑚𝑖
+1
𝑚𝐵
]1
2 𝑡𝑑
𝐸
𝐿
760
𝑃
𝑇
273.2
1
𝑁
Boltzmann constant
Charge on
an electron
Charge state of the
analyte ion
Reduced mass of
the ion and neutral
Number density
of the drift gas
Electric field
Molecular size
X-ray crystallography
Ion mobility (using Helium)
2014 Biopharma Roadshow
25
26
Standard Procedure for Calculating CCS (Auto Charting, Curve Fitting and Calculating the CCS)
2014 Biopharma Roadshow
Time segments with different drift fields
27
Collision Cross Section Benchmark --- Vanderbilt University
• Tetraalkylammonium salts (TAA)
• Proposed as an “ideal” ion mobility standard
• Wide CCS range (TAA-4 to TAA-18; 100 to 400 Å2)
• TAA salts do not form clusters
• Literature CCS values exist N2 drift gas
+2 ions
+3 ions
+1 ions TAA-16
TAA-18
TAA-12
TAA-10
TAA-8 TAA-7
TAA-6 TAA-5
TAA-4
0
10
30
40
200 400 600 800
0
20
Mo
bilit
y D
rift
Tim
e (
ms
)
Mass-to-Charge (m/z) 1000 1200
50
TAA-5 N-(CH2CH2CH2CH2CH3)4
2014 Biopharma Roadshow
28
Tetraalkylammonium Salts
--- CCS Values Compared to Literature
Analyte
Measured
Cross-Section
[Å2]
TAA-4 166.61 ± 0.5%
TAA-5 189.21 ± 0.6%
TAA-6 212.71 ± 0.3%
TAA-7 236.34 ± 0.2%
TAA-8 257.19 ± 0.1%
TAA-10 294.53 ± 0.1%
TAA-12 323.62 ± 0.2%
TAA-16 362.03 ± 0.2%
TAA-18 381.58 ± 0.3%
Literature
Cross-Section
[Å2]
166.00 ± 0.3%
190.10 ± 0.1%
214.00 ± 0.3%
236.80 ± 0.2%
258.30 ± 0.4%
Relative Standard
Deviation
[%]
0.56
0.28
0.41
0.01
0.24
• High experimental precision
(< 0.5% relative deviation)
• Agreement with literature
(most < 0.5% deviation)
2014 Biopharma Roadshow
29
Cross Section Calculation of Ubiquitin Charge States
1000 1500 2000 2500 3000
m/z 1713.9, [M+5H]5+
m/z 1428.4, [M+6H]6+
m/z 1224.4, [M+7H]7+
m/z 1071.6, [M+8H]8+
m/z 952.6, [M+9H]9+
m/z 857.5, [M+10H]10+
m/z 779.6, [M+11H]11+
m/z 714.7, [M+12H]12+
m/z 659.8, [M+13H]13+
m/z 612.8, [M+14H]14+
Automated
collision cross
section calculation
without the use of
calibration curves approximate
region for
compact
structures approximate
region for
elongated
structures
Reference: Koeniger and Clemmer J Am Soc Mass Spectrom 2007, 18, 322-331
(Å)
2014 Biopharma Roadshow
30
Cross Section Calculation of Ubiquitin Charge States
Ion Charge State CCS
experimental (Å2)
CCS
literature (Å2)
[M+5H]5+ 5 1196
[M+6H]6+ 6 1431, 1658
[M+7H]7+ 7 1755, 1886 1910
[M+8H]8+ 8 1966 1990
[M+9H]9+ 9 2008 2090
[M+10H]10+ 10 2114, 2197 2200
[M+11H]11+ 11 2239, 2348 2340
[M+12H]12+ 12 2412, 2511 2480
[M+13H]13+ 13 2556, 2620 2600
[M+14H]14+ 14 2680, 2726
Reference: Bush et al., Anal Chem. 2010, 82, 9557-9565.
Automated collision cross section calculation without the use of calibration curves
2014 Biopharma Roadshow
31
Carbohydrates -- Great complexity by linkage
Source: Blixt et al., PNAS, 2004
Current dominant strategies: MSn or Library searches
2014 Biopharma Roadshow
32
Carbohydrates IM-MS Io
n M
ob
ilit
y D
rift
Tim
e (
ms)
Mass (Da) 0
0
20
40
50
500 1000 1500 2000
10
30
60
Mixture of Lacto-N-difucohexaose I & II
Mass (Da)
1018 1022 1024 1026 1028 1020
Drift Time (ms)
37 39 40 41 42 38 36 35
Lacto-N-
difucohexaose II
Drift Time (ms)
37 39 40 41 42 38 36 35
Lacto-N-
difucohexaose I
Lacto-N-difucohexaose I
Lacto-N-difucohexaose II
Gal Glc Gal GlcNAc
Fuc Fuc
Gal Glc Gal GlcNAc
Fuc Fuc
2014 Biopharma Roadshow
33
IM Drift Spectrum on Cytochrome C at various RFs:
S1: Native
S2-S5: Denatured
• RF 90V
• RF 110V
• RF 130V
• RF 150V
• RF 180V
Waters
Synapt G2
IM data
S1
S2
S3
S4 S5
?
Preserve protein native
structures better! – Due
to the much lower ions
heating.
2014 Biopharma Roadshow
34
200 400 600 800 1000 1200 1400 1600
Drift Time (ms) vs. m/z
15
20
25
30
IMS-MS for Proteomics: Transmembrane Spanning Peptides of HeLa digest
Low dt High dt
2014 Biopharma Roadshow
770 771 772 773 774
Drift Time (ms) vs. m/z
22
23
24
25
26
27
28
29
High dt
Low dt
All Ions
Fragmentation
Low dt
35
A Word About Instrument Design
LC Drift IMS MS and MS/MS
High Resolution Accurate Mass
LC Q IMS MS
High Resolution Accurate Mass
Feature Agilent Waters Drift Mobility
Advantage
Mobility
Resolution
Highest (can be > 80)
80cm drift tube (L)
higher voltage (E)
No RF fields, Uniform low DC
field
Generally around 30
25cm drift TriWave,
Multi-section device
RF fields
Over 2X the IM
resolution of T-wave
Sensitivity High efficiency ion funnels -
trapping and rear
Step wave lens
Pressure barrier between
Q and TriWave
10X to 50X better
than T-wave
Collision Cross
Section (CCS)
measurement
(Ω)
Direct determination of Ω
Low electric field and
constant drift tube pressure
Ω cannot be directly
determined from drift
time.
Need calibration tables.
1-2% precision
Much better than
Synapt (5-10%)
Molecular
structures
Lower RF fields, less ion
heating.
Higher RF fields,
tendency for higher
fragmentation and ion
heating
Lower RF allows
preservation of
molecular structures
2014 Biopharma Roadshow
36
Summary
• Next generation of IM Q-TOF Technology
• Added dimension of separation based on size, charge and
molecular conformation
• Resolve and characterize the complex samples
-- Increased peak capacity
• Direct determination collision cross sections
• Preservation of molecular structures
2014 Biopharma Roadshow
2014 Biopharma Roadshow 37
Acknowledgments
Ruwan Kurulugama
Alex Mordehai
Mark Werlich
Chris Klein
Tom Knotts
Ed Darland
Gregor Overney
Bill Barry
Nathan Sanders
Lane Howard
Mikhail Ugarov
Gene Wong
Yergeny Kaplun
George Stafford
Bill Frazier
Bruce Wang
Huy Bui
Crystal Cody
John Fjelsted
Ken Imatani
Robert Kincaid
Robin Scheiderer
Collaborators:
PNNL
NIH
Texas A&M
Vanderbilt University
Boston University
Standard Procedure for Calculating CCS (Drift Time versus P/V Curves)
Reserpine Colchicine
Ondansetron y = 6258x + 5.5225R² = 0.9999
y = 8,019x + 7.2356R² = 0.9996
y = 5,410x + 4.9269R² = 1.0000
0
10
20
30
40
50
60
0 0.001 0.002 0.003 0.004 0.005 0.006D
rift
tim
e (m
s)P/V (Torr/V)
Colchicine Reserpine Ondansetron
39
Compound Drift time
(ms) Slope
Intercept
t0(ms)
Ondansetron 20.09 5410 4.9269
Colchicine 23.03 6258 5.5225
Reserpine 29.89 8019 7.2356
tD = experimental drift time
t0 = time ions spend out side
the drift cell
td = corrected drift time
2014 Biopharma Roadshow
39
40
Standard Procedure for Calculating CCS
- Auto Stepping the Low Field Gradient
Time segments with different drift fields
2014 Biopharma Roadshow
41
Conformational Space Occupancy of Biomolecules
C
oll
isio
n C
ros
s S
ec
tio
n (
Å2)
Mass (Da)
Hypothetical Ordering of
Biomolecular Classes
lipids
carbohydrates
peptides
oligonucleotides
2014 Biopharma Roadshow
42
Ion source maintained at ground potential (no voltage offset)
Uniform low static electric field across drift cell
• 80 cm long, approximately 20 V/cm with 4 Torr Nitrogen buffer gas
• Mobility resolution approaches theoretical limit
• Minimizes ion excitation or heating (helps to maintain ion structures and conformations)
Uniform low field ion mobility allows direct determination of accurate CCS (Ω)
~1700 V on chamber
Desolvation
chamber at 0 V
Uniform DC electric field
(no RF voltage applied)
Ion Mobility System Design
2014 Biopharma Roadshow